On January 17, 2017, pre-market, Alcobra revealed that its attention deficit hyperactivity disorder drug, Metadoxine Extended Release, failed to meet its primary endpoint in its Phase 3 trial. Following this news, Alcobra stock dropped $0.97 per share, or 50.82%, to close at $0.94 January 17, 2017.
If you are aware of any facts relating to this investigation, or purchased Alcobra shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/adhd. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-alcobra-ltd-adhd-300392288.html
SOURCE Bronstein, Gewirtz & Grossman, LLC